Gloomy First Half Results For Mayne
While Restructuring Gains Pace With $90m Generics Selloff
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
You may also be interested in...
Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
Mayne Agrees Deal For TherapeuticsMD’s US Women’s Health Portfolio
Mayne Pharma enters an exclusive US license agreement with TherapeuticsMD for the latter’s women’s health portfolio. Whether the deal will boost their precarious finances is an open question.
Mayne Pharma CEO Steps Down Amid $475m Metrics Contract Services Sale
Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.